To identify the differences between coronary heart disease risk in patients with altered basal glucemia (ABG), oral glucose intolerance (OGI) and type II diabetes mellitus according to the WHO-85 and ADA-97 diagnostic classifications, in an adult population at high risk for diabetes mellitus.
Moreover, the recent MIMOSA (MIld to MOderate acute pancreatitis: early naSogastric tube feeding compared with pAncreatic rest) trial compared in a randomized fashion early nasogastric tube feeding (commenced within 24 hours after hospital admission) with nil per os and found that nasogasric feeding does not exacerbate the course of AP and even reduces the risk of oral food intolerance [ 14].
In case of intolerance, oral dapsone (100 mg/day), aerosolized pentamidine (300 mg every 4 weeks) or oral atovaquone (at least 1,500 mg/day) may be used [ 66].
Intravenous zoledronic acid is especially attractive for patients with gastrointestinal contraindications to oral bisphosphonates, gastrointestinal intolerance to oral bisphosphonates, or malabsorption of oral bisphosphonates.
The indications for intravenous pamidronate were contraindications for oral bisphosphonates or intolerance for oral bisphosphonate therapy within three months from the start of treatment.
Patients had 1 or more of the following indications for local therapy: intolerance to oral medication, contraindication to oral medication because of pregnancy, lack of response despite oral antimicrobial treatment, or treatment with concomitant oral and local therapy to avoid or limit foveal or optic disc involvement.
The indication for treatment with pamidronate iv was intolerance of oral bisphosphonates (22), gastrointestinal complaints prior to treatment with oral bisphosphonates (4) and a contraindication for oral treatment (4).
The selection criteria in this study excluding patients with known intolerance to oral iron and severe disease activity may have caused a selection bias toward a favorable tolerability for oral iron.
Twenty-three consecutive patients (22 women, 1 man) diagnosed with HFEM and with an inadequate response or intolerance to oral preventatives were included.
Patients with CM and inadequate response or intolerance to oral preventatives were treated with pericranial injections of 100 U of TBA every 3 months.
Patients with known intolerance to oral iron were excluded.
